Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data Accessibility StatementSkip Navigation Combination of high quality, variable-rich, curated EHR data with genomics enhances understanding of the patient journey and aids in therapy development SAN FRANCISCO, March 24, 2026 /PRNewswire/ -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has announced a new partnership with leading ...

Guardant Health Inc. (NASDAQ:GH) is one of the most promising stocks under $100 to buy. On March 16, Guardant Health announced the launch of its Shield multi-cancer detection/MCD test in several Asian markets through a first-of-its-kind partnership with Manulife. This methylation-based blood test is designed to detect ten common types of cancer (including lung, breast, colorectal, and liver) in individuals aged 45 or older who are at typical risk. Starting in April, eligible Manulife customers in Hong Ko ...

Core Viewpoint - Guardant Health, Inc. is recognized as a promising growth stock with a Moderate Buy consensus from analysts, indicating strong potential for price appreciation in the near term [1][4]. Financial Performance - For Q4 2025, Guardant Health reported revenue of $281.3 million, reflecting a 39% year-over-year increase, with oncology revenue rising 30% to $189.9 million and screening revenue reaching $35.1 million [2]. - The company anticipates total revenue growth of 27% to 30% for the year 2026 [2]. Strategic Developments - At recent healthcare conferences, Guardant emphasized its partnership with Quest Diagnostics as a significant commercial driver for its Shield product, noting that the potential benefits from this partnership were not included in the 2026 revenue guidance [3]. - Management highlighted that 90% of Shield users had not been screened in the previous five years, suggesting a substantial opportunity for market expansion [3]. - Additional catalysts for growth include potential FDA-related advancements for ESR1 monitoring in Guardant360, although the Reveal Ultra product was excluded from 2026 guidance due to uncertain reimbursement [3]. Analyst Ratings - Piper Sandler analyst David Westenberg maintained a Buy rating on Guardant Health, raising the price target from $120 to $130 following the quarterly release [4].

Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026 Mar 18, 2026 8:05 AM Eastern Daylight Time Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026 Share PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, ...

Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Small Cap Fund”. A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise characteristics, with strong earnings trajectories, and are trading at a discount to the estimated private market value. Despite strong results in 2025, volatility was elevated, and sentiment shifted frequently, influenced by political developments in the US, evolving trade ...

Eltoukhy also pointed to increasing test capabilities—such as using methylation signals and other platform enhancements to better characterize tumor biology and histology—as helping move liquid biopsy into broader utility. He framed another long-term growth lever as repeated testing over the course of treatment, enabled by the expanding number of therapeutic options and the need to track tumor evolution.In discussing Guardant360, Co-CEO Helmy Eltoukhy described multiple drivers behind the franchise’s growth ...

Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership Mar 16, 2026 8:05 AM Eastern Daylight Time Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership Share PALO ALTO, Calif. & HONG KONG--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Shieldâ"¢ multi-cancer detection (MCD) laboratory developed test (L ...

Core Insights - A recent survey by Guardant Health and Harris Poll reveals that 92% of Americans aged 45 and over believe that blood-based colorectal cancer screening should be accessible and covered without co-pay, similar to Medicare [1] - The Shield test by Guardant Health, a non-invasive blood-based screening for colorectal cancer, has shown a 93% adherence rate, significantly improving screening rates compared to traditional methods [1] - The survey highlights barriers to colorectal cancer screening, with 54% of respondents finding stool-based tests unappealing and 71% expressing anxiety about colonoscopies [1] Company Overview - Guardant Health is a leading precision oncology company focused on enhancing patient care and accelerating cancer therapies through advanced blood and tissue tests [1] - The Shield test is the first and only FDA-approved blood test for primary colorectal cancer screening, intended for individuals aged 45 and older at average risk [1] - Guardant Health's Shield test is covered by Medicare, Veterans Affairs Community Care Network, and TRICARE, making it widely accessible across the U.S. [1] Industry Context - Colorectal cancer is the second leading cause of cancer-related deaths in the U.S., with a 91% five-year survival rate if detected early [1] - The U.S. Preventive Services Task Force updated national CRC screening guidelines in 2021, lowering the recommended screening age from 50 to 45, but has yet to include the new Shield test in its recommendations [1] - The National Comprehensive Cancer Network has recently included the Shield blood test in its updated CRC screening guidelines, indicating a shift towards improved patient access [1]

Core Viewpoint - The discussion centers around the clinical utility of the ESR1 mutation discovery and its implications for liquid biopsy, particularly in the context of the SERENA-6 protocol design [1] Group 1 - There are ongoing conversations regarding the SERENA-6 study and its protocol design, which have sparked interest and debate within the biotech community [1] - The clinical utility of identifying the ESR1 mutation is highlighted, emphasizing its broader implications for patient care and treatment decisions [1] - The focus is on the benefits of testing and the potential for patient outcomes without delving into specific drug discussions [1]

Summary of Guardant Health Conference Call Company Overview - **Company**: Guardant Health - **Industry**: Life Sciences Tools and Diagnostics Key Points Business Drivers and Growth Opportunities - Guardant Health has three major business drivers: treatment selection, minimal residual disease (MRD), and screening, all contributing to hypergrowth opportunities [4][5][6] - The SERENA-6 trial is a significant growth driver for Guardant360, focusing on liquid biopsy for treatment selection in breast cancer patients [4][9] - The FDA approval for the ESR1 mutation detection is anticipated in the first half of the year, which could double the volume of breast cancer testing [5][9] Clinical Utility and Testing - The ESR1 mutation is a mechanism of resistance in breast cancer, and its detection can influence treatment decisions [5][6] - Guardant360 is set to become the first monitoring companion diagnostic (CDx) for liquid biopsy, expanding its utility beyond single time-point testing [10][12] - The company has seen a significant increase in testing volume post-FDA approvals, which enhances conversations with commercial payers regarding reimbursement [12][14] Product Development and Technology - Guardant Health is leveraging a large database of genomic and epigenomic data to enhance its product offerings, including the development of Smart Apps for clinical information [13][14] - The Reveal product is the fastest-growing test in the portfolio, with expectations for continued growth in both adjuvant and surveillance settings [16][19] - The Reveal Ultra launch is anticipated later this year, with the potential for significant market impact, although it is not included in the 2026 revenue guidance due to uncertainties [35][36] Market Strategy and Adoption - The Shield product targets unscreened patient populations, with 90% of tested patients having not been screened in the last five years, indicating a substantial market opportunity [42][52] - Guardant Health is focusing on increasing productivity among existing sales representatives and expanding its sales force to drive growth [43][46] - The company is not yet competing directly with stool-based tests but is seeing some incidental use cases where patients prefer blood tests over traditional methods [52] Reimbursement and Financial Outlook - Current reimbursement for CRC surveillance is approximately $1,644, with expectations for similar levels for new products [36][37] - The company is optimistic about future reimbursement discussions as it continues to engage with commercial payers [12][37] Future Opportunities - There is potential for future advancements in MRD testing, including the ability to locate and characterize residual disease through the same test [24][32] - Guardant Health is exploring the integration of multi-omics data to enhance its diagnostic capabilities [13][14] Additional Insights - The company is strategically positioning itself to fill care gaps in cancer screening, particularly among populations that have not previously engaged with screening technologies [42][52] - Guardant Health's approach to direct-to-consumer (DTC) marketing is evolving, with a focus on educating consumers about the importance of screening [53][54]